Dark

NERV
Minerva Neurosciences, Inc
stock NASDAQ

At Close

Jun 29, 2026 3:59:56 PM EDT

5.41USD+23.913%(+1.04)379,818

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-4.37)0

After-hours

Jun 29, 2026 4:59:30 PM EDT

5.40USD-0.277%(-0.01)26,422

OverviewHistoricalExchangesShortsNews

Jan 11, 2022

04:50PM EST CORRECTION: Minerva Surgical Ticker Is 'UTRS' Benzinga

04:02PM EST Minerva Surgical Sees Prelim. Q4 Revenues $13.5M-$13.7M vs $13.45M Est., Sees Prelim. FY21 Sales $52M-$52.2M vs $51.75M Est. Benzinga

Nov 8, 2021

07:31AM EST Minerva Neurosciences Q3 EPS $(0.22), Inline Benzinga

07:30AM EST Minerva Neurosciences Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 3, 2021

09:20AM EDT Minerva Neurosciences Reports FDA Recommendation For Type C Meeting To Discuss Evidence For Use Of Roluperidone As Monotherapy For Treatment Of Negative Symptoms In Schizophrenia Patients Benzinga

08:30AM EDT Minerva Neurosciences Announces FDA Recommendation for Type C GlobeNewswire Inc

Nov 1, 2021

08:30AM EDT Minerva Neurosciences to Report Third Quarter 2021 Financial GlobeNewswire Inc

Oct 13, 2021

02:02PM EDT Watching Minerva Neurosciences Shares; Traders Circulate Patent Doc From Australian Gov't. For Co.'s 'Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia' Benzinga

Oct 11, 2021

08:32AM EDT Minerva Neurosciences Announces Promotion Of Geoff Race To President Benzinga

08:30AM EDT Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 1, 2021

06:05AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.45 A.M. EDT). RTTNews

Sep 30, 2021

08:45AM EDT Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence Of Phase 2b, Phase 3, And Planned Commercial Formulations Of Roluperidone For Treatment Of Negative Symptoms Of Schizophrenia; Says Study Met All Key Pharmacokinetic Objectives Benzinga

08:38AM EDT Minerva Neurosciences Announces Results From Pivotal Bioequivalence Study For Negative Symptoms Of Schizophrenia RTTNews

08:30AM EDT Minerva Neurosciences Announces Study Results Demonstrating GlobeNewswire Inc

Sep 8, 2021

08:30AM EDT Minerva Neurosciences Announces Appointment of Dr. Ramana GlobeNewswire Inc

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

Aug 2, 2021

07:33AM EDT Minerva Neurosciences Q2 EPS $(0.25) Misses $(0.17) Estimate Benzinga

07:30AM EDT Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2021. GlobeNewswire Inc

04:05AM EDT Earnings Scheduled For August 2, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 26, 2021

08:30AM EDT Minerva Neurosciences to Report Second Quarter 2021 Financial GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jun 10, 2021

08:30AM EDT Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual JMP Securities Life Sciences Conference on June 16, 2021 at 10:00 a.m. Eastern Time. GlobeNewswire Inc

May 28, 2021

08:00AM EDT Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time. GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

07:38AM EDT Minerva Neurosciences Q1 Net Loss $8.8 Mln Or $0.21/Shr Vs Loss $12.2 Mln Or $0.31/Shr Last Year RTTNews

07:38AM EDT Minerva Neurosciences Q1 EPS $(0.21) Up From $(0.31) YoY Benzinga

07:30AM EDT Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year GlobeNewswire Inc

06:59AM EDT Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning Benzinga

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

May 11, 2021

04:44PM EDT Minerva Neurosciences Announces Results Of 40-Week Open-Label Extension Of Phase 3 Trial Of Roluperidone; Mean Improvement In Positive Symptoms Was 1.9 Points In 32 mg Arm And 1.8 Points In 64 mg Arm Benzinga

04:15PM EDT Minerva Neurosciences Announces the Results of the Phase 3 Trial GlobeNewswire Inc

Mar 8, 2021

08:45AM EST Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 GlobeNewswire Inc

07:34AM EST Minerva Neurosciences Q4 EPS $(0.17) Beats $(0.19) Estimate Benzinga

04:05AM EST Earnings Scheduled For March 8, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 1, 2021

08:30AM EST Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and GlobeNewswire Inc

Feb 8, 2021

11:30AM EST Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Feb 6, 2021

10:00AM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead plaintiff deadline. GlobeNewswire Inc

Feb 5, 2021

09:15PM EST Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important February 8 Deadline - NERV PR Newswire

04:00PM EST IMMINENT SHAREHOLDER DEADLINE: Block & Leviton LLP Reminds GlobeNewswire Inc

Feb 4, 2021

11:00AM EST NERV Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Minerva Neurosciences, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: February 8, 2021 Business Wire

Feb 3, 2021

09:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

04:23PM EST NERV INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors GlobeNewswire Inc

03:15PM EST NERV FEB 8 DEADLINE: Pawar Law Group Announces a Securities Class GlobeNewswire Inc

Feb 2, 2021

08:01AM EST Portnoy Law: Lawsuit Filed On Behalf of Minerva Neurosciences, Inc GlobeNewswire Inc

Jan 31, 2021

05:06AM EST Investment in Minerva Neurosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - NERV PR Newswire

Jan 29, 2021

03:59PM EST WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead plaintiff deadline. GlobeNewswire Inc

10:00AM EST NERV & SMICY Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

08:00AM EST SHAREHOLDER ALERT: Block & Leviton LLP Reminds Shareholders that GlobeNewswire Inc

Jan 26, 2021

02:33PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 25, 2021

10:39AM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws. GlobeNewswire Inc

Jan 21, 2021

05:09PM EST Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - NERV PR Newswire

11:00AM EST BSX, NERV & SMICY Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Jan 20, 2021

06:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

09:17AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 19, 2021

08:30AM EST Royalty Pharma Acquires Royalty Interest in Seltorexant From GlobeNewswire Inc

08:03AM EST Royalty Pharma To Acquire Minerva Neurosciences' Seltorexant Royalty Interest For Upfront Payment Of $60M And Up To $95M In Milestone Payments Benzinga

08:00AM EST Minerva Neurosciences and Royalty Pharma Announce Sale of GlobeNewswire Inc

Jan 18, 2021

05:00PM EST ROSEN, A LEADING LAW FIRM, Reminds Minerva Neurosciences, Inc. GlobeNewswire Inc

10:43AM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

08:00AM EST SHAREHOLDER ALERT: Block & Leviton LLP Reminds Shareholders that GlobeNewswire Inc

Jan 14, 2021

12:06PM EST ROSEN, A LEADING LAW FIRM, Reminds Minerva Neurosciences, Inc. GlobeNewswire Inc

Jan 13, 2021

05:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

12:01PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 11, 2021

12:42PM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

08:00AM EST SHAREHOLDER ALERT: Block & Leviton LLP Reminds Shareholders that GlobeNewswire Inc

Jan 8, 2021

05:09PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Minerva investors under the federal securities laws. GlobeNewswire Inc

10:04AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Jan 6, 2021

07:45PM EST ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. PR Newswire

06:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

09:27AM EST Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

Jan 2, 2021

03:12PM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Dec 31, 2020

04:28PM EST Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the "Class Period"), of the important February 8, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Minerva investors under the federal securities laws. GlobeNewswire Inc

Dec 29, 2020

11:00AM EST BSX, NERV & SMICY Class Actions: Bronstein, Gewirtz & Grossman LLC GlobeNewswire Inc

Dec 28, 2020

12:03PM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Dec 24, 2020

10:02AM EST Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. PR Newswire

Dec 23, 2020

11:08AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 22, 2020

07:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

09:41AM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

09:00AM EST Notice of Lead Plaintiff Deadline for Shareholders in the Minerva Neurosciences, Inc. Class Action Lawsuit Business Wire

08:00AM EST LAWSUIT FILED: Block & Leviton LLP Reminds Shareholders that it GlobeNewswire Inc

Dec 20, 2020

12:25AM EST Pomerantz LLP is investigating claims on behalf of investors of Minerva Neurosciences, Inc. (Minerva or the Company) (NASDAQ:NERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Dec 18, 2020

12:14PM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 17, 2020

08:05PM EST INVESTOR FILING DEADLINES: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

11:00AM EST NERV Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Minerva Neurosciences, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: February 8, 2021 Business Wire

Dec 16, 2020

08:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

Dec 15, 2020

01:31PM EST Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws. GlobeNewswire Inc

10:00AM EST NERV Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC GlobeNewswire Inc

08:00AM EST LAWSUIT FILED: Block & Leviton LLP Reminds Shareholders that it GlobeNewswire Inc

Dec 12, 2020

09:27PM EST Pomerantz LLP is investigating claims on behalf of investors of Minerva Neurosciences, Inc. (Minerva or the Company) (NASDAQ:NERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Dec 11, 2020

11:44AM EST Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the Class Period). GlobeNewswire Inc

Dec 10, 2020

05:57PM EST INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a GlobeNewswire Inc

01:32PM EST NERV INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

10:01AM EST Neurosciences, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: February 8, 2021 PR Newswire

04:00AM EST NERV INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class PR Newswire

Dec 9, 2020

09:00PM EST Bragar Eagel & Squire, P.C. Reminds Investors That Class Action GlobeNewswire Inc

09:51AM EST Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

Dec 8, 2020

12:26PM EST LAWSUIT FILED: Block & Leviton LLP Announces that it Has Filed a GlobeNewswire Inc

Dec 7, 2020

08:16PM EST Pomerantz LLP is investigating claims on behalf of investors of Minerva Neurosciences, Inc. (Minerva or the Company) (NASDAQ:NERV). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Dec 1, 2020

02:32PM EST Mid-Afternoon Market Update: Gold Rises 2%; Tuniu Shares Drop After Q3 Results Benzinga

12:33PM EST Mid-Day Market Update: Crude Oil Down Over 1%; BlackBerry Shares Jump On Amazon Partnership Benzinga

10:21AM EST Mid-Morning Market Update: Markets Open Higher; Nio November Deliveries Surge 109% Benzinga

08:12AM EST Minerva Neurosciences Announces Outcome Of Type C Meeting With FDA And Next Steps In The Development Of Roluperidone Benzinga

08:00AM EST Minerva Neurosciences Announces Outcome of Type C Meeting with FDA GlobeNewswire Inc

07:08AM EST Minerva Neurosciences Inc.(NERV) disclosed in a regulatory filing that it has received official meeting minutes from the November 10 Type C meeting with the U.S. Food and Drug Administration regarding development of roluperidone for treatment of negative symptoms in schizophrenia. RTTNews

06:24AM EST Minerva Receives Official Meeting Minutes From November 10 Type C Meeting With FDA On Roluperidone RTTNews

06:15AM EST Minerva Neurosciences On Dec 1, Received Official Meeting Minutes From Co.'s Nov 10, Type C Meeting With FDA; Objective Of Meeting Was To Obtain FDA Input Regarding Roluperidone Data Package And Its Readiness To Support NDA Submission Benzinga

Nov 9, 2020

08:30AM EST Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST). GlobeNewswire Inc

Nov 2, 2020

09:44AM EST Minerva Neurosciences shares are trading higher after the company reported better-than-expected Q3 EPS results. Benzinga

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

07:41AM EST Minerva Neurosciences Q3 EPS $(0.19) Beats $(0.23) Estimate Benzinga

07:30AM EST Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2020. GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

08:30AM EDT Minerva Neurosciences to Report Third Quarter 2020 Financial GlobeNewswire Inc

Oct 13, 2020

02:58PM EDT Minerva Neurosciences Shares Spike Higher; Co Granted U.S. Patent Titled 'Compositions and methods for treating schizophrenia' Benzinga

Sep 9, 2020

08:30AM EDT Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 10:00 a.m. Eastern Time. GlobeNewswire Inc

Sep 2, 2020

08:30AM EDT Minerva Neurosciences to Present at Citi's 15th Annual BioPharma GlobeNewswire Inc

Aug 13, 2020

08:00AM EDT Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities CNS Forum on August 19, 2020 at 10:30 a.m. Eastern Time. This event will be held virtually. GlobeNewswire Inc

Aug 3, 2020

07:36AM EDT Minerva Neurosciences Q2 EPS $0.75, May Not Compare To $(0.29) Estimate Benzinga

07:30AM EDT Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2020. GlobeNewswire Inc

04:13AM EDT Earnings Scheduled For August 3, 2020 Benzinga

Jul 27, 2020

08:01AM EDT Minerva Neurosciences to Report Second Quarter 2020 Financial GlobeNewswire Inc